A study of WTX212A with or without radiation for advanced cancer
Part of Cancer clinical trials.
This trial tests a new drug (WTX212A) alone or with radiation therapy for people with advanced solid tumors. It aims to see if the treatment is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that has been confirmed by a biopsy or other lab test.
- You are between 18 and 75 years old.
- You do not have serious heart, lung, or other internal medical conditions that are not well controlled.
- You do not have fluid buildup that requires regular drainage.
- You have not had to permanently stop an immunotherapy drug because of side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, HWS116, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink tumors or slow their growth.
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
This trial tests a new drug called WTX212A for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to find the best dose and see if the drug is safe and effective.
This trial tests a new drug, AWT020, for people with advanced cancer (solid tumors or lymphoma) that hasn't responded to other treatments. The goal is to see if it is safe and how well it works.
This early-stage trial tests a new allogeneic cell therapy (WTX-212C) designed to fight advanced solid cancers. Researchers want to see if this treatment is safe and how well it works in patients whose cancer has spread.
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.